Podium to Practice: ESMO® 2025 – Lung: IDeate-Lung01

Podium to Practice: ESMO® 2025 – Lung: IDeate-Lung01

Podium to Practice: ESMO® 2025
Explore more from your favourite experts – click their name to access their entire library of content.
Icon Chair Speaker

Chair

Dr. Barbara Melosky

Icon Chair Speaker

Speakers

Dr. Rosalyn Juergens

Dr. Peter Ellis

Studies / Trials Discussed

2760MO – Intracranial activity of ifinatamab deruxtecan (I-DXd) in patients (pts) with extensive-stage (ES) small cell lung cancer (SCLC) and baseline (BL) brain metastases (BM): Primary analysis of IDeate-Lung01

Studies/trials discussed:

2760MO – Intracranial activity of ifinatamab deruxtecan (I-DXd) in patients (pts) with extensive-stage (ES) small cell lung cancer (SCLC) and baseline (BL) brain metastases (BM): Primary analysis of IDeate-Lung01
Tagged